Crux Biomedical

Press Enter or Click Search to perform a full site search.

Company Name Matches

Show All Search Results »

Related Jobs

Jobs by SimplyHired

Companies>Crux Biomedical

Add to Watch List Share This Page

Email Page Flag This Page

Flag

Website: http://www.cruxbiomedical.com/

Crux Biomedical The company is developing a retrievable Inferior Vena Cava (IVC) Filter that promises to be a great improvement over existing modes of treatment. The device has been successfully tested in animal studies in 2006 and was recently implanted in humans. Crux is currently working with the FDA to design and implement large-scale human clinical trials. The clinical trials should...More»

Address: 3270 Alpine Road Menlo Park, CA 94028 Map it »

Phone: 650-851-2332

Email: info@cruxbiomedical.com

Founded: 2004

Industry: Medical Devices & Equipment

Sub-Industry: Therapeutic Devices

Legal Structure: Corporation

Ownership: Private

Tags:

Add a tag

Management

Board of Directors

Date	Type	Capital Amount	Post-Money Valuation	Investors
11/30/2007	Series B	2.25M	Unknown	Alloy Ventures, Growth Capital, Hercules Technology Growth Capital

Name:	Vena Cava Filters
Product URL:	http://www.cruxbiomedical.com/technology.htm
Description:	DVT/PE Inferior vena cava filters (IVCF) are designed to prevent an often fatal condition known as pulmonary embolism (PE). PE is caused by migration of a large blood clot arising from deep veins of the legs, a condition known as deep vein thrombosis (DVT). Every year in the United States, approximately 600,000 patients develop a PE and between 120,000 - 150,000 are fatal. Inferior Vena Cava Filters With the introduction of the Greenfield IVCF in 1973, physicians had the option of implanting a filter in the inferior vena cava to prevent potentially deadly pulmonary embolisms. Initially this filter was implanted surgically and designed as a permanent implant. With the advent of new medical technology and new biomaterials, IVCF’s have evolved. Most notably, improvements included filters that could be delivered using minimally invasive techniques, (through small catheters) and subsequently removed from the patient (optional filters). Optional filters first approved by the FDA in 2003 have the advantage that they can be left in permanently, or at the physician’s discretion, retrieved at a later date. While currently approved IVC filters are very effective at preventing PE, incidence of IVCF tilting (potentially making device retrieval impossible), migration and penetration through the wall of the inferior vena cava have been reported. Source: Johnson, Matthew S., MD. “Retrievable and Permanent IVC Filter: Indications, Use, Results.” Indiana School of Medicine.